Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, posted on X:
“Following the presentation of the landmark DeLLphi-304 trial on Tarlatamab vs SoC Chemotherapy in patients with pre-treated SCLC in ASCO25.
Join Dr Jacob Sands and me on June 17th in a hands-on, comprehensive read-out discussion on DLL-3 T-cell engagers and SCLC hosted by 1 and only Solange Peters.”
More posts featuring Giannis Mountzios.